Results 1 to 10 of about 4,497 (116)

Transcriptional responses of Biomphalaria pfeifferi and Schistosoma mansoni following exposure to niclosamide, with evidence for a synergistic effect on snails following exposure to both stressors. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2019
BackgroundSchistosomiasis is one of the world's most common NTDs. Successful control operations often target snail vectors with the molluscicide niclosamide.
Sarah K Buddenborg   +5 more
doaj   +4 more sources

Niclosamide Modulates the Cellular and Humoral Immune Response in Balb/c Mice [PDF]

open access: yesIranian Journal of Immunology, 2022
Background: Niclosamide, a STAT3 inhibitor, is widely under investigation due to its anti-cancer properties. STAT3 also exhibits an exciting role in the immune responses.
Bilal Mahmood Beg   +5 more
doaj   +1 more source

Protective Effect of Niclosamide on Lipopolysaccharide-induced Sepsis in Mice by Modulating STAT3 Pathway

open access: yesKorean Journal of Clinical Laboratory Science, 2023
Sepsis is a systemic inflammatory response, with manifestations in multiple organs by pathogenic infection. Currently, there are no promising therapeutic strategies.
Se Gwang JANG
doaj   +1 more source

The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2018
BACKGROUND:The antiparasitic agent niclosamide has been demonstrated to inhibit the arthropod-borne Zika virus. Here, we investigated the antiviral capacity of niclosamide against dengue virus (DENV) serotype 2 infection in vitro and in vivo.
Jo-Chi Kao   +8 more
doaj   +1 more source

The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression

open access: yesCell Death and Disease, 2022
Niclosamide, a cell-permeable salicylanilide, was approved by the Food and Drug Administration for its anthelmintic efficiency. A growing body of evidence in recent years suggests that niclosamide exhibits potential tumor-suppressive activity.
Yangyang Guo   +9 more
doaj   +1 more source

Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]

open access: yesPeerJ, 2023
Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri   +9 more
doaj   +2 more sources

Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

open access: yesAAPS Open, 2023
Motivation The low solubility, weak acid drug, niclosamide is a host cell modulator with broad-spectrum anti-viral cell-activity against many viruses, including stopping the SARS-CoV-2 virus from infecting cells in cell culture.
David Needham
doaj   +1 more source

The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. [PDF]

open access: yesPLoS ONE, 2014
Breast carcinoma is the most common female cancer with considerable metastatic potential. Discovery of new therapeutic approaches for treatment of metastatic breast cancer is still needed.
Tinghong Ye   +12 more
doaj   +1 more source

Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution

open access: yesPharmaceutics, 2022
Niclosamide is an FDA-approved anthelmintic that is being studied in clinical trials as a chemotherapeutic and broad-spectrum antiviral. Additionally, several other applications are currently in the preclinical stage.
Miguel O. Jara   +7 more
doaj   +1 more source

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment

open access: yesVaccines, 2022
Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating ...
Jesse W. Wotring   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy